Načítá se...
Targeted therapy for idiopathic pulmonary fibrosis: where to now?
Idiopathic pulmonary fibrosis (IPF) is an aging-associated recalcitrant lung disease with historically limited therapeutic options. The recent approval of two drugs, pirfenidone and nintedanib, by the United States Food and Drug Administration (FDA) in 2014 has heralded a new era in its management....
Uloženo v:
| Vydáno v: | Drugs |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4939080/ https://ncbi.nlm.nih.gov/pubmed/26729185 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-015-0523-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|